Cytokinetics Inc.
CYTKStock
$80.36+117.36%52W
Market Cap$10.06B
P/E—
Div yield—
Beta0.32
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)16.83%
Price vs S&P 500 (4W)9.26%
VGM Score54.54
Market Capitalization$10.06B
Earnings Surprise History
Q1 26-1.67est. -1.69
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.04
4.04
4.07
4.11
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CYTKCytokinetics Inc. | F | A | B | $80.36 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Cytokinetics is a late-stage biopharmaceutical company developing small-molecule muscle activators and inhibitors for serious cardiovascular and neuromuscular diseases, including heart failure, amyotrophic lateral sclerosis, spinal muscular atrophy, and chronic obstructive pulmonary disease. Its investigational medicines enhance muscle function and contractility in patients with compromised muscle performance. The company targets large patient populations with significant unmet medical needs and limited treatment options.